 CureVac BV NASDAQ: CVAC has canceled contract manufacturing deals for its experimental COVID-19 vaccine with two prospective partners. The Company would terminate agreements with Celonic Group and Wacker, but existing production deals with Rentschler Biopharma and Novartis AG NYSE: NVS would remain unchanged. 